TNFSF11 and osteoporosis: Thus, our findings reveal that PLCβ4 controls osteoclastogenesis via the RANKL-dependent MKK3–p38 MAPK pathway and that PLCβ4 may be a potential therapeutic candidate for bone diseases such as osteoporosis.